Blog
RSS FeedPosted by Michael Wonder on 21 Aug 2017
AbbVie’s Maviret approved by Health Canada for the treatment of chronic hepatitis C in all major genotypes
17 August 2017 - Maviret is the first and only 8-week, pan-genotypic treatment for hepatitis C patients without cirrhosis and who ...
Posted by Michael Wonder on 20 Aug 2017
Gilead receives approval in Canada for Vosevi (sofosbuvir/velpatasvir/voxilaprevir) for re-treatment of certain patients with chronic hepatitis C virus infection
17 August 2017 - VOSEVI is the first once daily, single tablet hepatitis C virus (HCV) regimen for re-treatment, and ...
Posted by Michael Wonder on 16 Aug 2017
Health Canada approves Ocrevus (ocrelizumab) for Canadians living with relapsing-remitting multiple sclerosis
15 August 2017 - Ocrevus is a first-in-class treatment that targets B-cells, offering a new pathway to treat multiple sclerosis. ...
Posted by Michael Wonder on 14 Aug 2017
Onivyde (irinotecan liposome for injection) has received approval in Canada for the treatment of metastatic adenocarcinoma of the pancreas in the post-gemcitabine setting
11 August 2017 - Onivyde, in combination with 5-fluorouracil and leucovorin, is the first and only treatment shown to increase ...
Posted by Michael Wonder on 10 Aug 2017
Berinert approved by Health Canada for the treatment of hereditary angioedema in paediatric patients
9 August 2017 - CSL Behring is pleased to announce that on 31 March 2017 Berinert (C1 esterase inhibitor, human) was ...
Posted by Michael Wonder on 26 Jul 2017
Health Canada approves Adcetris (brentuximab vedotin) for the post-ASCT consolidation treatment of patients with Hodgkin lymphoma at increased risk of relapse or progression
25 July 2017 - Approval based on positive phase 3 AETHERA clinical trial results. ...
Posted by Michael Wonder on 23 Jul 2017
Sunovion’s Latuda (lurasidone hydrochloride) receives Health Canada approval to treat adolescents with schizophrenia
21 July 2017 - Health Canada has also accepted for review a supplemental new drug submission for Latuda for the ...
Posted by Michael Wonder on 18 Jul 2017
Cardiome announces Health Canada approval of Aggrastat high dose bolus regimen
17 July 2017 - Cardiome Pharma Corporation today announced that the Therapeutic Products Directorate of Health Canada has approved the ...
Posted by Michael Wonder on 05 Jul 2017
Biogen's Spinraza (nusinersen) receives Notice of Compliance from Health Canada for the treatment of 5q spinal muscular atrophy
4 July 2017 - First SMA treatment approval in Canada. ...
Posted by Michael Wonder on 26 Jun 2017
BioDelivery Sciences announces Health Canada approval of Belbuca
23 June 2017 - BioDelivery Sciences announced that Health Canada, the regulatory authority in Canada, has issued a notice of compliance ...
Posted by Michael Wonder on 22 Jun 2017
Pfizer receives expanded Health Canada approval for Ibrance
21 June 2017 - New indication supported by results of Phase 3 PALOMA-3 trial of Ibrance in combination with fulvestrant. ...
Posted by Michael Wonder on 20 Jun 2017
Horizon Pharma announces Health Canada approval of Procysbi (cysteamine delayed release capsules) for the treatment of nephropathic cystinosis
19 June 2017 - Horizon Pharma today announced that Health Canada has issued a notice of compliance for Procysbi (cysteamine delayed-release ...
Posted by Michael Wonder on 19 Jun 2017
Gilead receives approval in Canada for Vemlidy (tenofovir alafenamide) for the treatment of chronic hepatitis B virus infection
19 June 2017 - Vemlidy is a once-daily treatment that demonstrated similar efficacy with improved renal and bone laboratory safety ...
Posted by Michael Wonder on 16 Jun 2017
Combination treatment Tafinlar (dabrafenib) plus Mekinist (trametinib) approved by Health Canada to treat BRAF V600-positive metastatic non-small cell lung cancer after prior systemic therapy
15 June 2017 - Only approved targeted therapy combination for patients with BRAF V600-positive NSCLC. ...
Posted by Michael Wonder on 31 May 2017
Kineret approved in Canada for the treatment of neonatal-onset multisystem inflammatory disease (NOMID)
30 May 2017 - Sobi Canada today announces that Health Canada has approved Kineret (anakinra) for the treatment of neonatal-onset ...